ITGAV and atherosclerosis: For example, endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis and stimulate plaque regression using a lower (one-third) dose of the drug, as compared to that borne by non-targeted nanoparticles showing a similar regressive effect on the plaque [262].